UA116894C2 - Похідні піразину як агоністи канабіноїдного рецептора 2 - Google Patents
Похідні піразину як агоністи канабіноїдного рецептора 2Info
- Publication number
- UA116894C2 UA116894C2 UAA201506212A UAA201506212A UA116894C2 UA 116894 C2 UA116894 C2 UA 116894C2 UA A201506212 A UAA201506212 A UA A201506212A UA A201506212 A UAA201506212 A UA A201506212A UA 116894 C2 UA116894 C2 UA 116894C2
- Authority
- UA
- Ukraine
- Prior art keywords
- receptor agonists
- pyrazine derivatives
- novel pyrazine
- novel
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196024 | 2012-12-07 | ||
| PCT/EP2013/075444 WO2014086807A1 (en) | 2012-12-07 | 2013-12-04 | Novel pyrazine derivatives as cb2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116894C2 true UA116894C2 (uk) | 2018-05-25 |
Family
ID=47290805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201506212A UA116894C2 (uk) | 2012-12-07 | 2013-12-04 | Похідні піразину як агоністи канабіноїдного рецептора 2 |
Country Status (32)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6514119B2 (ja) | 2013-03-07 | 2019-05-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ピラゾール誘導体 |
| NO2978755T3 (enExample) | 2013-03-26 | 2018-06-02 | ||
| PE20151977A1 (es) | 2013-05-02 | 2016-01-07 | Hoffmann La Roche | Nuevos derivados de purina |
| KR20160002857A (ko) | 2013-05-02 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체 |
| KR20220140651A (ko) | 2013-09-06 | 2022-10-18 | 에프. 호프만-라 로슈 아게 | 신규의 트라이아졸로[4,5-d]피리미딘 유도체 |
| CA2943013A1 (en) * | 2014-04-04 | 2015-10-08 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| DK3386951T3 (en) * | 2015-12-09 | 2020-04-27 | Hoffmann La Roche | Phenylderivater som cannabinoidreceptor-2-agonister |
| JP7300398B2 (ja) | 2017-06-20 | 2023-06-29 | エフ． ホフマン－ラ ロシュ アーゲー | ピリジン誘導体 |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| CN112074513B (zh) | 2018-06-27 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 作为优先大麻素2激动剂的吡啶和吡嗪衍生物 |
| BR112020025013A2 (pt) * | 2018-06-27 | 2021-03-23 | F. Hoffmann-La Roche Ag | novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| EP2076499B1 (en) * | 2006-10-04 | 2010-05-12 | F.Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
-
2013
- 2013-12-04 RS RS20170313A patent/RS55951B1/sr unknown
- 2013-12-04 SG SG11201504011UA patent/SG11201504011UA/en unknown
- 2013-12-04 PT PT137995452T patent/PT2928882T/pt unknown
- 2013-12-04 PL PL13799545T patent/PL2928882T3/pl unknown
- 2013-12-04 SI SI201330591A patent/SI2928882T1/sl unknown
- 2013-12-04 BR BR112015009603A patent/BR112015009603A2/pt not_active Application Discontinuation
- 2013-12-04 CN CN201380063228.9A patent/CN104837830B/zh not_active Expired - Fee Related
- 2013-12-04 CA CA2885418A patent/CA2885418A1/en not_active Abandoned
- 2013-12-04 DK DK13799545.2T patent/DK2928882T3/en active
- 2013-12-04 KR KR1020157014961A patent/KR20150092156A/ko not_active Withdrawn
- 2013-12-04 ES ES13799545.2T patent/ES2621958T3/es active Active
- 2013-12-04 MX MX2015006036A patent/MX2015006036A/es unknown
- 2013-12-04 EP EP13799545.2A patent/EP2928882B1/en not_active Not-in-force
- 2013-12-04 IN IN3145DEN2015 patent/IN2015DN03145A/en unknown
- 2013-12-04 AU AU2013354115A patent/AU2013354115B2/en not_active Ceased
- 2013-12-04 UA UAA201506212A patent/UA116894C2/uk unknown
- 2013-12-04 MA MA38217A patent/MA38217B1/fr unknown
- 2013-12-04 HU HUE13799545A patent/HUE030836T2/en unknown
- 2013-12-04 EA EA201590827A patent/EA025840B1/ru not_active IP Right Cessation
- 2013-12-04 PE PE2015000736A patent/PE20151060A1/es not_active Application Discontinuation
- 2013-12-04 HR HRP20170572TT patent/HRP20170572T1/hr unknown
- 2013-12-04 JP JP2015545985A patent/JP6322646B2/ja active Active
- 2013-12-04 LT LTEP13799545.2T patent/LT2928882T/lt unknown
- 2013-12-04 US US14/648,399 patent/US9512141B2/en not_active Expired - Fee Related
- 2013-12-04 WO PCT/EP2013/075444 patent/WO2014086807A1/en not_active Ceased
- 2013-12-05 AR ARP130104504A patent/AR093804A1/es unknown
- 2013-12-06 TW TW102144989A patent/TW201427960A/zh unknown
-
2015
- 2015-03-26 IL IL237982A patent/IL237982A/en not_active IP Right Cessation
- 2015-04-22 CR CR20150210A patent/CR20150210A/es unknown
- 2015-05-14 PH PH12015501072A patent/PH12015501072A1/en unknown
- 2015-05-15 CL CL2015001318A patent/CL2015001318A1/es unknown
-
2017
- 2017-04-07 CY CY20171100418T patent/CY1118808T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116894C2 (uk) | Похідні піразину як агоністи канабіноїдного рецептора 2 | |
| PH12015502524A1 (en) | New somatostatin receptor subtype 4 (sstr4) agonists | |
| UA114657C2 (uk) | Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2 | |
| NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
| UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
| MX2011008602A (es) | Metodos de tratamiento de condiciones relacionadas con el cabello. | |
| GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
| MD20150122A2 (ro) | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 | |
| PH12015501339A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
| CY1118848T1 (el) | Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| MX2013001234A (es) | Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a. | |
| MX2016005759A (es) | Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| PH12016501849A1 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | |
| UA116801C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 | |
| MY149154A (en) | Novel microbiocides | |
| PH12015501146A1 (en) | Hydantoin derivative | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| MX360001B (es) | Compuestos de acrilamida como ligandos receptores de histamina h3. | |
| WO2013048949A3 (en) | Selective nr2b antagonists | |
| IN2012DN02698A (enExample) | ||
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| MX2015000804A (es) | Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1. | |
| GB201119089D0 (en) | Treatment of musculoskeletal fibroproliferative disorders |